Acumen Pharmaceuticals Inc [ABOS] stock prices are up 2.50%% to $1.23 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ABOS shares have gain 14.95% over the last week, with a monthly amount glided 18.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acumen Pharmaceuticals Inc [NASDAQ: ABOS] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $4. Previously, Citigroup started tracking the stock with Buy rating on July 26, 2024, and set its price target to $7. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $8 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $13 as its price target on May 18, 2023. BTIG Research started tracking with a Buy rating for this stock on July 15, 2022, and assigned it a price target of $15. In a note dated June 30, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $15 on this stock.
The stock price of Acumen Pharmaceuticals Inc [ABOS] has been fluctuating between $0.86 and $3.60 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Acumen Pharmaceuticals Inc [NASDAQ: ABOS] shares were valued at $1.23 at the most recent close of the market. An investor can expect a potential return of 469.11% based on the average ABOS price forecast.
Analyzing the ABOS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.58 and Total Capital is -0.68. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1667 points at the first support level, and at 1.1033 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2767, and for the 2nd resistance point, it is at 1.3233.
Ratios To Look Out For
It’s worth pointing out that Acumen Pharmaceuticals Inc [NASDAQ:ABOS]’s Current Ratio is 8.02. In addition, the Quick Ratio stands at 8.02 and the Cash Ratio stands at 1.56.
Transactions by insiders
Recent insider trading involved Zuga Matt, CFO & Chief Business Officer, that happened on Jan 23 ’25 when 28902.0 shares were sold. CFO & Chief Business Officer, Zuga Matt completed a deal on Jan 21 ’25 to sell 4364.0 shares. Meanwhile, Chief Executive Officer OConnell Daniel Joseph sold 12619.0 shares on Jan 21 ’25.
